UPC (Universe Pharmaceuticals) Beneish M-Score: -2.61 (As of Jun. 26, 2026)


UPC Universe Pharmaceuticals Inc UPC
58 GF Score
Price $2.77
GF Value $5.22
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Universe Pharmaceuticals Beneish M-Score?

Universe Pharmaceuticals UPC -2.81% 58 Beneish M-Score is -2.61 as of Jun. 26, 2026. GuruFocus rates UPC with a GF Score™ of 58/100 and a GF Value™ of $5.22 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 911 Drug Manufacturers companies, Universe Pharmaceuticals ranks better than 60.15% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.61 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Universe Pharmaceuticals's Beneish M-Score or its related term are showing as below:

UPC' s Beneish M-Score Range Over the Past 10 Years
Min: -3.54   Med: -2.3   Max: -1.01
Current: -2.61

During the past 8 years, the highest Beneish M-Score of Universe Pharmaceuticals was -1.01. The lowest was -3.54. And the median was -2.30.

Universe Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Universe Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universe Pharmaceuticals Beneish M-Score Chart

Universe Pharmaceuticals Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beneish M-Score
Get a 7-Day Free Trial -1.01 -3.54 -3.20 -1.98 -2.61

Universe Pharmaceuticals Semi-Annual Data
Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.20 0.00 -1.98 0.00 -2.61

UPC vs CBIH, PRFX, IMCC: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universe Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Universe Pharmaceuticals's Beneish M-Score falls into.


UPC
58GF Score
Universe Pharmaceuticals Inc UPC
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Universe Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Universe Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9509+0.528 * 0.7475+0.404 * 1.0037+0.892 * 0.7757+0.115 * 0.9039
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0445+4.679 * 0.027474-0.327 * 0.5754
=-2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep25) TTM:Last Year (Sep24) TTM:
Total Receivables was $13.19 Mil.
Revenue was $17.86 Mil.
Gross Profit was $6.30 Mil.
Total Current Assets was $53.60 Mil.
Total Assets was $69.30 Mil.
Property, Plant and Equipment(Net PPE) was $14.70 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.52 Mil.
Selling, General, & Admin. Expense(SGA) was $8.00 Mil.
Total Current Liabilities was $13.17 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was $-3.67 Mil.
Gross Profit was $-0.52 Mil.
Cash Flow from Operations was $-5.05 Mil.
 Total Receivables was $17.88 Mil.
Revenue was $23.02 Mil.
Gross Profit was $6.07 Mil.
Total Current Assets was $51.64 Mil.
Total Assets was $67.95 Mil.
Property, Plant and Equipment(Net PPE) was $15.34 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.49 Mil.
Selling, General, & Admin. Expense(SGA) was $9.88 Mil.
Total Current Liabilities was $20.31 Mil.
Long-Term Debt & Capital Lease Obligation was $2.14 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(13.186 / 17.859) / (17.877 / 23.024)
=0.738339 / 0.776451
=0.9509

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6.072 / 23.024) / (6.301 / 17.859)
=0.263725 / 0.352819
=0.7475

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (53.604 + 14.701) / 69.303) / (1 - (51.638 + 15.34) / 67.953)
=0.014401 / 0.014348
=1.0037

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=17.859 / 23.024
=0.7757

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.486 / (0.486 + 15.34)) / (0.517 / (0.517 + 14.701))
=0.030709 / 0.033973
=0.9039

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(8.002 / 17.859) / (9.877 / 23.024)
=0.448065 / 0.428987
=1.0445

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 13.174) / 69.303) / ((2.137 + 20.313) / 67.953)
=0.190093 / 0.330375
=0.5754

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3.672 - -0.524 - -5.052) / 69.303
=0.027474

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Universe Pharmaceuticals has a M-score of -2.61 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.61 mean?
Universe Pharmaceuticals (UPC) has a Beneish M-Score of -2.61 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Universe Pharmaceuticals and its competitors. According to the industry distribution chart, Universe Pharmaceuticals ranks #363 out of 911 companies in the Drug Manufacturers industry, placing it in the top 39.8%.
Is Universe Pharmaceuticals' Beneish M-Score too high?
Universe Pharmaceuticals' current Beneish M-Score is -2.61. Based on the distribution chart, Universe Pharmaceuticals ranks #363 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Universe Pharmaceuticals has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Beneish M-Score compare to CBIH and PRFX?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #363 out of 911 companies for Beneish M-Score. This puts Universe Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Universe Pharmaceuticals and its competitors. Universe Pharmaceuticals's current Beneish M-Score is -2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Possible Value Trap. The stock's GF Value™ is $5.22, compared to a current price of $2.77 — trading 46.9% below its estimated fair value. The current Beneish M-Score is -2.61. Universe Pharmaceuticals' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Beneish M-Score is -2.61 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Universe Pharmaceuticals (UPC) Overvalued in 2026?

Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be undervalued. The current stock price of $2.77 is trading 46.9% below its estimated GF Value™ of $5.22. GuruFocus considers Universe Pharmaceuticals to be Possible Value Trap.

Key valuation signals for UPC:

  • Beneish M-Score: -2.61
  • GF Value™: $5.22 vs. price of $2.77 (46.9% below fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Universe Pharmaceuticals Business Description

Address 265 Jingjiu Avenue, Jinggangshan Economic & Technological Development Zone, Jiangxi, Ji’an, CHN, 343100
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
58GF Score

Get the complete analysis for UPC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77
Price
$5.22
GF Value